Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Lymphoma 5Lung Neoplasms 5Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Neuroblastoma 3Neoplasms 2Hematologic Neoplasms 2Carcinoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Neurofibromatosis 2 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Carcinoma, Large Cell 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1Advanced Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1ALK-positive NSCLC 1ALK or ROS1-positive NSCLC 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Crizotinib × Clear all
NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Columbia University

Phase 2 Completed
34 enrolled 9 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡